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Background: Pandemic Influenza A (H1N1) 2009 is a novel viral infection that emerged in March 2009. This is the
first report addressing the clinical course of patients with cystic fibrosis (CF) and H1N1 infection.
Methods: All patients with an influenza-like illness (ILI) attending our adult centre during July 2009 were identified.
Baseline respiratory function, nutritional status, approach to management and short-term clinical course were recorded.
Results: Most patients experienced a mild course and were able to be managed with antiviral agents as an
outpatient. Robust infection control policies were implemented to limit transmission of H1N1 infection within our
CF centre. Patients with severe lung disease, poor baseline nutritional reserve and presenting with more than 48
hours of ILI experienced a more severe course. Prompt antiviral therapy within the first 48 hours of illness may
have been important in improving outcomes.
Conclusions: This observational study demonstrates that most adults with CF with H1N1 infection had mild clinical
courses and recovered rapidly.
Background
H1N1 is a novel influenza virus containing a combina-
tion of gene segments from North American and Eura-
sian swine lineages [1]. The first reported cases of
human H1N1 infection emerged from Mexico in March
2009 [2]. Widespread availability of airline travel con-
tributed to the novel virus’ ability to move quickly to
other continents [3].
Viral infections are well recognised precipitants of
acute deterioration in the clinical status of patients with
cystic fibrosis [4-9]. Increased respiratory symptoms and
hospitalisation and reduced pulmonary function are
seen during a viral infection [8]. There have been some
reports that a longer-term deleterious effect may also be
attributable to severe viral infection [5,8].
Viral infections also contribute to clinical deterioration
by altering lower airway defences against bacterial infec-
tion. For example, new Pseudomonas aeruginosa
infection has been noted to peak during winter periods
when viral infections are common [8,10]. RSV have
been shown to compromise airways defences via damage
to airway epithelium and depletion of the periciliary
layer (PCL) [11]. Influenza A virus has also been shown
to accelerate neutrophil apoptosis [12].
This is the first report of the outcomes seen in CF
patients infected with Pandemic (H1N1) 2009. Our
experience provides some insights in the management
of H1N1-infected patients with CF.
Method
Patients with an influenza-like illness (ILI) at our centre
in July 2009 were identified. An ILI was defined as
recent fever, with one or more of the following: sore
throat, myalgias, rhinorrhea, headache and gastrointest-
inal symptoms. CF centre nursing staff performed the
swab if a clinical diagnosis of ILI had been made.
Three dry sterile swabs were used to collect samples;
two from the nasopharynx and one from the posterior
oropharynx. Molecular detection using a multiplex assay
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H1N1-specific polymerase chain reaction (PCR) assay
was then performed by the Molecular Viral Laboratory
of QLD Pathology [13].
After 22 July 2009, patients were treated on clinical
suspicion and no longer swabbed, in accordance with
t h ep o l i c yo fo u rs t a t eg o v e r nment health authority.
Subsequently, only people presenting with ILI from the
following groups were tested: pregnant women, indigen-
ous people, hospitalised patients and healthcare workers.
This study was approved by The Prince Charles Hos-
pital Research, Ethics and Governance Committee. Indi-
vidual patient consent for the study was not required by
the Ethics Committee.
Results
Twelve of our 270 patients (4.4%) presented with an ILI
during the month of July 2009, including 11 confirmed
by swab and one who was treated after a clinical diagno-
sis of H1N1. Only one patient reported contact with a
known H1N1- infected person. All infections were com-
munity-acquired and no patients reported recent travel
overseas. During this period a further five patients pre-
sented with ILI and subsequently had negative H1N1
2009 PCR assays. One of these patients had a positive
PCR for respiratory syncytial viral infection, and the
other four patients did not have other respiratory viral
infections detected.
Two patients were admitted after initial management
at home with oseltamivir and antibiotic therapy, includ-
ing one patient admitted on day four of symptoms with
large volume haemoptysis and moderate infective
exacerbation of bronchiectasis. He had co-infection with
human metapneumovirus and sought early discharge
from hospital. The second patient had a diagnosis of
H1N1 infection made on the basis of clinical presenta-
tion and treated in the community with oseltamivir for
five days. Within 36 hours of completing therapy, she
was admitted with a recrudescence of viral symptoms.
Swabs were collected and confirmed the presence of
H1N1 2009 infection. She was recommenced on oselta-
mivir therapy for a further five days and was discharged
48 hours after hospitalisation.
Symptoms at presentation were variable. Fever (92%),
increased cough (92%), rhinorrhea (75%) and myalgias
(67%) were most commonly seen. Headache and sore
throat occurred in one third of patients. There were 7
males and 5 females in the cohort with a mean FEV1%
predicted of 66% (SD 20) and a mean BMI of 22 (SD 5)
kg/m
2. The mean age of our H1N1 affected CF patients
was notably lower than our total CF clinic mean age ie.
22 years (SD 3) compared with 28 years (SD 9). Baseline
characteristics of the patients and their management are
summarised in Additional File 1. Notably all patients
reported here had chronic P. aeruginosa infection. The
clinical course was variable however overall was mild.
Seven of the patients required admission to hospital and
four of these were hospitalised for a period of 7 days or
less.
Patients with ILI were commenced immediately on a
five day course of oseltamivir 75 mg twice daily. In
accordance with current recommendations for other
high risk groups, all patients were prescribed oseltamivir
even if they presented with symptoms of more than 48
hours duration. Oseltamivir was well tolerated with no
treatment cessation due to side effects.
Discussion
The outcomes for patients with H1N1 2009 infection
and CF have not been previously described. Known risk
groups including pregnant women, people with a
chronic illness, including respiratory disease, indigenous
groups, obese people and immunosuppressed hosts [14].
The first Australian case of H1N1 infection was
reported on 8 May 2009 [15].
World Health Organisation data suggests that the
majority of cases are occurring in people aged 12 to 17
years and the USA reports that 60% of cases are 18
years or less [16]. The median age of patients with
H1N1 infection in Australia is 21 years [17]. Our series
supports this observation with the mean age of our
H1N1 affected group lower than that of our CF clinic.
Symptoms in the 12 patients reported in our series
were variable. The diagnosis on clinical grounds alone is
more challenging in patients with a chronic respiratory
symptomatology. One patient developed more severe ILI
symptoms after the cessation of oseltamivir, which may
represented two discrete viral infections or may have
had a recrudescence of H1N1 infection at the cessation
of antiviral treatment. Patients with severe airflow
obstruction experienced more severe respiratory exacer-
bations, especially if they presented with ILI of more
than forty-eight hours duration.
The experience of our centre provides an opportunity
to formulate some suggestions for management CF
patients during an influenza pandemic. Firstly, ensuring
that CF centre staff are skilled in performing nasophar-
yngeal swabs allows rapid testing and limit movement of
the patient throughout the hospital. Secondly, encoura-
ging patients with ILI to notify the CF centre prior to
presenting to the outpatient clinic allows rapid isolation
of these patients. Early written correspondence with the
patient group will assist with education of patients
regarding best practice with ILI. Thirdly, establishment
of practical policies for management of suspected H1N1
infected patients allows all staff access to rapid decision-
making regarding management, 24 hours a day includ-
ing strict isolation with droplet precautions. Our
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oped protocols for management of all suspected H1N1
patients. These were readily able to be adapted to our
CF population. A policy for the early use of antiviral
agents may offer the greatest opportunity for avoidance
of severe H1N1-related disease.
By the end of July 21,668 cases of H1N1 2009 had been
reported across Australia [18] and by November this had
increased to greater than 37,000 cases [19]. Deaths attri-
butable to H1N1 2009 infection in Australia were 189 by
November 2009 [19]. This is likely to be an underesti-
mate of the true numbers of cases [20]. The frequency of
ILI seen in our patient group was lower than may have
been expected, given the large number of cases in the
community during July 2009. There may be patients with
ILI who did not notify the CF centre and self-managed
their illness. Patients may also have had H1N1 infection
which was undetected as they have attributed the symp-
toms to their underlying respiratory illness and not
sought medical review. Another possible explanation may
be that CF patients are more attentive to hand hygiene
and avoidance of people with viral symptoms than may
be expected of the general community.
As a result of the vast number of nasopharyngeal swab
tests performed during July 2009 a change in H1N1
testing was required and subsequently only patients with
ILI and risk factors for an adverse outcome (e.g. pre-
existing cardiorespiratory disease) had viral testing per-
formed [20]. Patients without ILI were not tested for
H1N1 2009 during the pandemic period. Consequently,
the rates of asymptomatic or minimally symptomatic
H1N1 infection in this population could not be esti-
mated. Furthermore, only one patient was detected to
have another respiratory virus (human metapneumo-
virus) as generally when H1N1 testing was positive addi-
tional respiratory viral testing was not performed.
During the month of August, another 13 cases of H1N1
infection were seen with similar clinical impact in the
initial cohort described here.
Since this analysis was performed, the H1N1 vaccina-
tion has been released (6
th October 2009) and has been
made freely available by the Commonwealth Government
to all Australians. The Adult Cystic Fibrosis Centre at
The Prince Charles Hospital has notified patients attend-
ing the Centre of its availability during hospital atten-
dance, and we have vaccinated all consenting patients
who did not have H1N1 2009 infection and this process
is ongoing. Despite the impact of the recent pandemic,
some patients have elected not to be vaccinated to date.
Conclusions
Despite significant symptoms, many of our patients were
successfully managed in the community with prompt
commencement of oseltamivir and supported by
appropriate antibiotic therapy. Patients with severe lung
disease, poor nutritional reserve and presenting late with
ILI experienced severe exacerbations characterised by
hypoxaemia and required prolonged hospitalisation.
Additional file 1: Table 1. Baseline characteristics and early outcomes of
patients with influenza-like illness.
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